Back to News
Market Impact: 0.25
Climb Bio Shares Rise On CLYM116 Data Supporting Every-12-Week Dosing
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Climb Bio (CLYM) reported positive initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, citing a prolonged half-life and deep, durable suppression of APRIL, IgA, and Gd-IgA1. While early-stage, the response durability profile is a meaningful efficacy signal that can support ongoing development expectations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
CLYM0.60
More News
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- Bessent proposes U.S.-China AI safety system in talks with China
- Here are the 3 big things we're watching in the stock market this week
- Tech leads shares higher in Asia, oil eases
- China slows humanoid robot IPO rush as hype outruns reality
- Société Générale présente une feuille de route stratégique ambitieuse portée par une exécution disciplinée